Lilly licenses orforglipron from Chugai

Eli Lilly and Company licensed orforglipron, the drug now sold as Foundayo, from Chugai Pharmaceutical Co., Ltd. of Japan in 2018 ^[1]. Lilly's official company materials describe orforglipron as having been "discovered by Chugai Pharmaceutical Co., Ltd. and licensed by Lilly in 2018," and the company repeats this attribution in its Foundayo press releases ^[1].

That licensing deal is the origin point for what Lilly now calls its second FDA-approved obesity medicine. On April 1, 2026, the FDA approved Foundayo for adults with obesity, or adults with overweight who also have weight-related medical problems, to be used alongside a reduced-calorie diet and increased physical activity ^[1]. Unlike Lilly's other GLP-1 medicines, which are injections, Foundayo is a once-daily pill that can be taken at any time of day without restrictions on food or water intake ^[1].

Orforglipron is a non-peptide, small-molecule GLP-1 receptor agonist, a chemical design that differs from the peptide-based molecules used in semaglutide (sold as Ozempic, Wegovy and Rybelsus) and tirzepatide (sold as Mounjaro and Zepbound) ^[1]. In Lilly's Phase 3 ATTAIN-1 trial, adults who took the highest dose of Foundayo and stayed on treatment for 72 weeks lost an average of 27.3 pounds, or 12.4% of body weight, compared with 2.2 pounds, or 0.9%, for those on placebo ^[1]. Counting all participants regardless of whether they completed the trial, average weight loss was 25 pounds, or 11.1%, versus 5.3 pounds, or 2.1%, on placebo ^[1]. The ATTAIN program, which enrolled more than 4,500 people across two global trials, also found that orforglipron reduced waist circumference, non-HDL cholesterol, triglycerides and systolic blood pressure across all doses tested ^[1].

Why it matters for patients

The eight-year gap between Lilly's 2018 licensing deal and the drug's 2026 approval reflects how long obesity drug development can take, from acquiring a molecule through years of clinical trials before it reaches pharmacy shelves ^[1]. For patients, the practical result is a new oral option in a category historically dominated by injectable drugs. Lilly says Foundayo can be taken without the meal-timing or liquid restrictions that apply to some other oral GLP-1 products, which the company frames as a convenience advantage for people who want pill-based treatment ^[1].

Cost and access details tied to the approval are also relevant to patients weighing their options. Lilly says eligible people with commercial insurance may pay as little as $25 per month with a savings card, while self-pay patients can access the lowest dose starting at $149 per month ^[1]. Eligible Medicare Part D patients may be able to get Foundayo for $50 per month beginning as soon as July 1, 2026, according to Lilly ^[1]. The drug carries a boxed warning about the risk of thyroid tumors, including thyroid cancer, and should not be used by people with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 ^[1]. Common side effects reported in trials include nausea, constipation, diarrhea, vomiting, indigestion, abdominal pain, headache, fatigue, and hair loss ^[1].

What happens next

Lilly says prescriptions for Foundayo were accepted immediately after approval, with shipping through LillyDirect beginning April 6, 2026, followed by broader availability through retail pharmacies and telehealth providers ^[1]. The company has also submitted orforglipron for approval in more than 40 countries and plans to launch it in each country shortly after local approval ^[1]. Beyond weight management, Lilly says orforglipron is being studied for type 2 diabetes, obstructive sleep apnea, osteoarthritis knee pain, hypertension, peripheral artery disease and stress urinary incontinence, though those uses are not yet approved ^[1].